Hypoxia in cancer: Significance and impact on clinical outcome

Cancer and Metastasis Reviews

Volumn 26, Issue 2, 2007, Pages 225-239

  Vaupel, Peter ^a   Mayer, Arnulf ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Hypoxia; Hypoxia imaging; Hypoxia marker; Oxygen needle electrode; Patient outcome; Tumor oxygenation

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ANTIINFECTIVE AGENT; CARBOGEN; CARBOXYHEMOGLOBIN; COPPER 64; GLUCOSE REGULATED PROTEIN 78; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTATE DEHYDROGENASE ISOENZYME; NICOTINAMIDE; OSTEOPONTIN; OXYGEN; PROTEIN LYSINE 6 OXIDASE; RADIOPHARMACEUTICAL AGENT; TAMOXIFEN; TECHNETIUM 99M; TIRAPAZAMINE; TRACER; VASCULOTROPIN;

APOPTOSIS; BLOOD OXYGENATION; BREAST CANCER; CANCER; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ASSESSMENT; HEAD AND NECK CANCER; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MALIGNANT NEOPLASTIC DISEASE; NECROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN SENSING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOFT TISSUE SARCOMA; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TUMOR GROWTH; UTERINE CERVIX CANCER;

CELL HYPOXIA; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 34547121206     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-007-9055-1     Document Type: Review

References (144)

1. Vaupel, P., Thews, O., & Höckel, M. (2001). Treatment resistance of solid tumors: Role of hypoxia and anemia. Medical Oncology, 18, 243-259.
2. Vaupel, P., & Höckel, M. (2002). Tumor hypoxia and therapeutic resistance. In M. R. Nowrousian (Ed.), Recombinant Human Erythropoietin (rhEPO) in clinical oncology (pp. 127-146). Berlin Heidelberg New York: Springer.
3. Vaupel, P., Mayer, A., & Höckel, M. (2004). Tumor hypoxia and malignant progression. Methods in Enzymology, 381, 335-354.
4. Vaupel, P., & Kelleher, D. K. (1999). Tumor hypoxia. Stuttgart: Wissenschaftliche Verlagsgesellschaft.
5. Vaupel, P., Briest, S., & Höckel, M. (2002). Hypoxia in breast cancer: Pathogenesis, characterization and biological/therapeutic implications. Wiener Medizinische Wochenschrift, 152, 334-342.
6. Vaupel, P., & Mayer, A. (2005). Effects of anaemia and hypoxia on tumour biology. In C. Bokemeyer & H. Ludwig (Eds.), European school of oncology. Scientific Updates, vol 6 (pp. 47-66).
7. 2 histography. Antioxidants & Redox Signalling (in press).
8. Vaupel, P. (2004). Tumor microenvironmental physiology and its implications for radiation oncology. Seminars in Radiation Oncology, 14, 198-206.
9. Höckel, M., & Vaupel, P. (2001). Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. Journal of the National Cancer Institute, 93, 266-276.
10. Semenza, G. L. (2000). Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Critical Reviews in Biochemistry and Molecular Biology, 35, 71-103.
11. Semenza, G. L. (2002). Involvement of hypoxia-inducible factor 1 in human cancer. Internal Medicine, 41, 79-83.
12. Semenza, G. L. (2002). HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends in Molecular Medicine, 8, S62-S67.
13. Harris, A. L. (2002). Hypoxia-A key regulatory factor in tumour growth. Nature Reviews Cancer, 2, 38-47.
14. Leo, C., Giaccia, A. J., & Denko, N. C. (2004). The hypoxic tumor microenvironment and gene expression. Seminars in Radiation Oncology, 14, 207-214.
15. Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. Nature Reviews. Cancer, 3, 721-732.
16. Reynolds, T. Y., Rockwell, S., & Glazer, P. M. (1996). Genetic instability induced by the tumor microenvironment. Cancer Research, 56, 5754-5757.
17. Yuan, J., Narayanan, L., Rockwell, S., & Glazer, P. M. (2000). Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Research, 60, 4372-4376.
18. Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., et al. (1996). Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature, 379, 88-91.
19. Kim, C. Y., Tsai, M. H., Osmanian, C., Graeber, T. G., Lee, J. E., Giffard, R. G., et al. (1997). Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Research, 57, 4200-4204.
20. Kondo, A., Safaei, R., Mishima, M., Niedner, H., Lin, X., & Howell, S. B. (2001). Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair. Cancer Research, 61, 7603-7607.
21. Vaupel, P. (2004). The role of hypoxia-induced factors in tumor progression. Oncologist, 9(Suppl 5), 10-17.
22. Gatenby, R. A., Kessler, H. B., Rosenblum, J. S., Coia, L. R., Moldofsky, P. J., Hartz, W. H., et al. (1988). Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. International Journal of Radiation Oncology, Biology, Physics, 14, 831-838.
23. Höckel, M., Schlenger, K., Aral, B., Mitze, M., Schäffer, U., & Vaupel, P. (1996). Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Research, 56, 4509-4515.
24. 2 predicts survival in advanced cancer of the uterine cervix. Radiotherapy and Oncology, 26, 45-50.
25. Fyles, A., Milosevic, M., Hedley, D., Pintilie, M., Levin, W., Manchul, L., et al. (2002). Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. Journal of Clinical Oncology, 20, 680-687.
26. 2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiotherapy and Oncology, 53, 99-104.
27. Lyng, H., Sundfor, K., Trope, C., & Rofstad, E. K. (2000). Disease control of uterine cervical cancer: Relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy. Clinical Cancer Research, 6, 1104-1112.
28. Evans, S. M., & Koch, C. J. (2003). Prognostic significance of tumor oxygenation in humans. Cancer Letter, 195, 1-16.
29. 2 in human cervix carcinomas after radiation therapy: A prospective international multi-center study. Radiotherapy and Oncology, 80, 123-131.
30. Nordsmark, M., Bentzen, S. M., Rudat, V., Brizel, D., Lartigau, E., Stadler, P., et al. (2005). Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiotherapy and Oncology, 77, 18-24.
31. Terris, D. J. (2000). Head and neck cancer: The importance of oxygen. Laryngoscope, 110, 697-707.
32. Menon, C., & Fraker, D. L. (2005). Tumor oxygenation status as a prognostic marker. Cancer Letter, 221, 225-235.
33. Mayer, A., Höckel, M., & Vaupel, P. (2006). Endogenous hypoxia markers in locally advanced cancers of the uterine cervix: Reality or wishful thinking? Strahlentherapie und Onkologie, 182, 501-510.
34. Bilton, R. L., & Booker, G. W. (2003). The subtle side to hypoxia inducible factor (HIFα) regulation. European Journal of Biochemistry, 270, 791-798.
35. Loeb, L. A. (1991). Mutator phenotype may be required for multistage carcinogenesis. Cancer Research, 51, 3075-3079.
36. Kwon, S. J., & Lee, Y. J. (2005). Effect of low glutamine/glucose on hypoxia-induced elevation of hypoxia-inducible factor-1α in human pancreatic cancer MiaPaCa-2 and human prostatic cancer DU-145 cells. Clinical Cancer Research, 11, 4694-4700.
37. +: Implications for HIF and hypoxic cell memory. Cell Cycle, 3, 1027-1029.
38. Bos, R., van der Groep, P., Greijer, A. E., Shvarts, A., Meijer, S., Pinedo, H. M., et al. (2003). Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer, 97, 1573-1581.
39. Gruber, G., Greiner, R. H., Hlushchuk, R., Aebersold, D. M., Altermatt, H. J., Berclaz, G., et al. (2004). Hypoxia-inducible factor 1 alpha in high-risk breast cancer: An independent prognostic parameter? Breast Cancer Research, 6, R191-R198.
40. Vleugel, M. M., Greijer, A. E., Shvarts, A., van der Groep, P., van Berkel, M., Aarbodem, Y., et al. (2005). Differential prognostic impact of hypoxia induced and diffuse HIF-1α expression in invasive breast cancer. Journal of Clinical Pathology, 58, 172-177.
41. Trastour, C., Benizri, E., Ettore, F., Ramaioli, A., Chamorey, E., Pouyssegur, J., et al. (2007). HIF-1alpha and CA IX staining in invasive breast carcinomas: Prognosis and treatment outcome. International Journal of Cancer, 120, 1451-1458.
42. Aebersold, D. M., Burri, P., Beer, K. T., Laissue, J., Djonov, V., Greiner, R. H., et al. (2001). Expression of hypoxia-inducible factor-1α: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Research, 61, 2911-2916.
43. Matsuyama, T., Nakanishi, K., Hayashi, T., Yoshizumi, Y., Aiko, S., Sugiura, Y., et al. (2005). Expression of hypoxia-inducible factor-1alpha in esophageal squamous cell carcinoma. Cancer Science, 96, 176-182.
44. Griffiths, E. A., Pritchard, S. A., Valentine, H. R., Whitchelo, N., Bishop, P. W., Ebert, M. P., et al. (2007). Hypoxia-inducible factor-1a expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. British Journal of Cancer, 96, 95-103.
45. Swinson, D. E., Jones, J. L., Cox, G., Richardson, D., Harris, A. L., & O'Byrne, K. J. (2004). Hypoxia-inducible factor-1 alpha in non small cell lung cancer: Relation to growth factor, protease and apoptosis pathways. International Journal of Cancer, 111, 43-50.
46. Burri, P., Djonov, V., Aebersold, D. M., Lindel, K., Studer, U., Altermatt, H. J., et al. (2003). Significant correlation of hypoxia-inducible factor-1α with treatment outcome in cervical cancer treated with radical radiotherapy. International Journal of Radiation Oncology, Biology, Physics, 56, 494-501.
47. Haugland, H. K., Vukovic, V., Pintilie, M., Fyles, A. W., Milosevic, M., Hill, R. P., et al. (2002). Expression of hypoxia-inducible factor-1α in cervical carcinomas: Correlation with tumor oxygenation. International Journal of Radiation Oncology, Biology, Physics, 53, 854-861.
48. Hutchison, G. J., Valentine, H. R., Loncaster, J. A., Davidson, S. E., Hunter, R. D., Roberts, S. A., et al. (2004). Hypoxia-inducible factor 1α expression as an intrinsic marker of hypoxia: Correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clinical Cancer Research, 10, 8405-8412.
49. Mayer, A., Wree, A., Höckel, M., Leo, C., Pilch, H., & Vaupel, P. (2004). Lack of correlation between expression of HIF-1α protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uterine cervix. Cancer Research, 64, 5876-5881.
50. Acs, G., Xu, X., Chu, C., Acs, P., & Verma, A. (2004). Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer, 100, 2376-2386.
51. Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Simopoulos, C., Turley, H., Talks, K., et al. (2002). Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. International Journal of Radiation Oncology, Biology, Physics, 53, 1192-1202.
52. Giatromanolaki, A., Koukourakis, M. I., Sivridis, E., Turley, H., Talks, K., Pezzella, F., et al. (2001). Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. British Journal of Cancer, 85, 881-890.
53. Atkin, G. K., Daley, F. M., Bourne, S., Glynne-Jones, R., Northover, J. M., & Wilson, G. D. (2006). The impact of surgically induced ischaemia on protein levels in patients undergoing rectal cancer surgery. British Journal of Cancer, 95, 928-933.
54. Ryan, H. E., Poloni, M., McNulty, W., Elson, D., Gassmann, M., Arbeit, J. M., et al. (2000). Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Research, 60, 4010-4015.
55. Maxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I. J., et al. (1997). Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 94, 8104-8109.
56. Carmeliet, P., Dor, Y., Herbert, J. M., Fukumura, D., Brusselmans, K., Dewerchin, M., et al. (1998). Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature, 394, 485-490.
57. Leek, R. D., Stratford, I., & Harris, A. L. (2005). The role of hypoxia-inducible factor-1 in three-dimensional tumor growth, apoptosis, and regulation by the insulin-signaling pathway. Cancer Research, 65, 4147-4152.
58. Volm, M., & Koomagi, R. (2000). Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Research, 20, 1527-1533.
59. Beasley, N. J., Leek, R., Alam, M., Turley, H., Cox, G. J., Gatter, K., et al. (2002). Hypoxia-inducible factors HIF-1α and HIF-2α in head and neck cancer: Relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Research, 62, 2493-2497.
60. Koukourakis, M. I., Bentzen, S. M., Giatromanolaki, A., Wilson, G. D., Daley, F. M., Saunders, M. I., et al. (2006). Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. Journal of Clinical Oncology, 24, 727-735.
61. Talks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., et al. (2000). The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. American Journal of Pathology, 157, 411-421.
62. Onita, T., Ji, P. G., Xuan, J. W., Sakai, H., Kanetake, H., Maxwell, P. H., et al. (2002). Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2α correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. Clinical Cancer Research, 8, 471-480.
63. Kang, S. S., Chun, Y. K., Hur, M. H., Lee, H. K., Kim, Y. J., Hong, S. R., et al. (2002). Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma. Japanese Journal of Cancer Research, 93, 1123-1128.
64. Kunkel, M., Reichert, T. E., Benz, P., Lehr, H. A., Jeong, J. H., Wieand, S., et al. (2003). Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer, 97, 1015-1024.
65. Tohma, T., Okazumi, S., Makino, H., Cho, A., Mochizuki, R., Shuto, K., et al. (2005). Overexpression of glucose transporter 1 in esophageal squamous cell carcinomas: A marker for poor prognosis. Diseases of the Esophagus, 18, 185-189.
66. Hoskin, P. J., Sibtain, A., Daley, F. M., & Wilson, G. D. (2003). GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: Relationship with vascularity and proliferation as predictors of outcome of ARCON. British Journal of Cancer, 89, 1290-1297.
67. Kawamura, T., Kusakabe, T., Sugino, T., Watanabe, K., Fukuda, T., Nashimoto, A., et al. (2001). Expression of glucose transporter-1 in human gastric carcinoma: Association with tumor aggressiveness, metastasis, and patient survival. Cancer, 92, 634-641.
68. Furudoi, A., Tanaka, S., Haruma, K., Yoshihara, M., Sumii, K., Kajiyama, G., et al. (2001). Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. Oncology, 60, 162-169.
69. Cantuaria, G., Fagotti, A., Ferrandina, G., Magalhaes, A., Nadji, M., Angioli, R., et al. (2001). GLUT-1 expression in ovarian carcinoma: Association with survival and response to chemotherapy. Cancer, 92, 1144-1150.
70. Younes, M., Brown, R. W., Stephenson, M., Gondo, M., & Cagle, P. T. (1997). Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer, 80, 1046-1051.
71. Airley, R., Loncaster, J., Davidson, S., Bromley, M., Roberts, S., Patterson, A., et al. (2001). Glucose transporter Glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clinical Cancer Research, 7, 928-934.
72. Mayer, A., Höckel, M., Wree, A., & Vaupel, P. (2005). Microregional expression of glucose transporter-1 and oxygenation status: Lack of correlation in locally advanced cervical cancers. Clinical Cancer Research, 11, 2768-2773.
73. Loncaster, J. A., Harris, A. L., Davidson, S. E., Logue, J. P., Hunter, R. D., Wycoff, C. C., et al. (2001). Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: Correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Research, 61, 6394-6399.
74. Chia, S. K., Wykoff, C. C., Watson, P. H., Han, C., Leek, R. D., Pastorek, J., et al. (2001). Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. Journal of Clinical Oncology, 19, 3660-3668.
75. Kon-no, H., Ishii, G., Nagai, K., Yoshida, J., Nishimura, M., Nara, M., et al. (2006). Carbonic anhydrase IX expression is associated with tumor progression and a poor prognosis of lung adenocarcinoma. Lung Cancer, 54, 409-418.
76. Chen, J., Rocken, C., Hoffmann, J., Kruger, S., Lendeckel, U., Rocco, A., et al. (2005). Expression of carbonic anhydrase 9 at the invasion front of gastric cancers. Gut, 54, 920-927.
77. Bui, M. H., Seligson, D., Han, K. R., Pantuck, A. J., Dorey, F. J., Huang, Y., et al. (2003). Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clinical Cancer Research, 9, 802-811.
78. Robertson, N., Potter, C., & Harris, A. L. (2004). Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Research, 64, 6160-6165.
79. Parkkila, S., Rajaniemi, H., Parkkila, A. K., Kivela, J., Waheed, A., Pastorekova, S., et al. (2000). Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proceedings of the National Academy of Sciences of the United States of America, 97, 2220-2224.
80. Potter, C., & Harris, A. L. (2004). Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle, 3, 164-167.
81. Lagadic-Gossmann, D., Huc, L., & Lecureur, V. (2004). Alterations of intracellular pH homeostasis in apoptosis: Origins and roles. Cell Death and Differentiation, 11, 953-961.
82. Toi, M., Matsumoto, T., & Bando, H. (2001). Vascular endothelial growth factor: Its prognostic, predictive, and therapeutic implications. Lancet Oncology, 2, 667-673.
83. Kotch, L. E., Iyer, N. V., Laughner, E., & Semenza, G. L. (1999). Defective vascularization of HIF-1alpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Developments in Biologicals, 209, 254-267.
84. Marjon, P. L., Bobrovnikova-Marjon, E. V., & Abcouwer, S. F. (2004). Expression of the pro-angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 by human breast carcinomas is responsive to nutrient deprivation and endoplasmic reticulum stress. Molecular Cancer, 3, 4.
85. Xu, L., Fukumura, D., & Jain, R. K. (2002). Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: Mechanism of low pH-induced VEGF. Journal of Biological Chemistry, 277, 11368-11374.
86. West, C. M., Cooper, R. A., Loncaster, J. A., Wilks, D. P., & Bromley, M. (2001). Tumor vascularity: A histological measure of angiogenesis and hypoxia. Cancer Research, 61, 2907-2910.
87. Raleigh, J. A., Calkins-Adams, D. P., Rinker, L. H., Ballenger, C. A., Weissler, M. C., Fowler, W. C. Jr., et al. (1998). Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Research, 58, 3765-3768.
88. Erler, J. T., & Giaccia, A. J. (2006). Lysyl oxidase mediates hypoxic control of metastasis. Cancer Research, 66, 10238-10241.
89. Erler, J. T., Bennewith, K. L., Nicolau, M., Dornhofer, N., Kong, C., Le, Q. T., et al. (2006). Lysyl oxidase is essential for hypoxia-induced metastasis. Nature, 440, 1222-1226.
90. Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Bougioukas, G., Didilis, V., Gatter, K. C., et al. (2003). Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. British Journal of Cancer, 89, 877-885.
91. Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Gatter, K. C., & Harris, A. L. (2006). Lactate dehydrogenase 5 expression in operable colorectal cancer: Strong association with survival and activated vascular endothelial growth factor pathway-A report of the Tumour Angiogenesis Research Group. Journal of Clinical Oncology, 24, 4301-4308.
92. Maulik, N., & Das, D. K. (2002). Redox signaling in vascular angiogenesis. Free Radical Biology & Medicine, 33, 1047-1060.
93. Rangaswami, H., Bulbule, A., & Kundu, G. C. (2006). Osteopontin: Role in cell signaling and cancer progression. Trends in Cell Biology, 16, 79-87.
94. Zhu, Y., Denhardt, D. T., Cao, H., Sutphin, P. D., Koong, A. C., Giaccia, A. J., et al. (2005). Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene, 24, 6555-6563.
95. Le, Q. T., Sutphin, P. D., Raychaudhuri, S., Yu, S. C., Terris, D. J., Lin, H. S., et al. (2003). Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clinical Cancer Research, 9, 59-67.
96. Le, Q. T., Chen, E., Salim, A., Cao, H., Kong, C. S., Whyte, R., et al. (2006). An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clinical Cancer Research, 12, 1507-1514.
97. Bache, M., Reddemann, R., Said, H. M., Holzhausen, H. J., Taubert, H., Becker, A., et al. (2006). Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: Prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels. International Journal of Radiation Oncology, Biology, Physics, 66, 1481-1487.
98. Nordsmark, M., Loncaster, J., Chou, S. C., Havsteen, H., Lindegaard, J. C., Davidson, S. E., et al. (2001). Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma. International Journal of Radiation Oncology, Biology, Physics, 49, 581-586.
99. Nordsmark, M., Loncaster, J., Aquino-Parsons, C., Chou, S. C., Ladekarl, M., Havsteen, H., et al. (2003). Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiotherapy and Oncology, 67, 35-44.
100. Evans, S. M., Judy, K. D., Dunphy, I., Jenkins, W. T., Nelson, P. T., Collins, R., et al. (2004). Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Research, 64, 1886-1892.
101. Kavanagh, M. C., Tsang, V., Chow, S., Koch, C., Hedley, D., Minkin, S., et al. (1999). A comparison in individual murine tumors of techniques for measuring oxygen levels. International Journal of Radiation Oncology, Biology, Physics, 44, 1137-1146.
102. Evans, S. M., Fraker, D., Hahn, S. M., Gleason, K., Jenkins, W. T., Jenkins, K., et al. (2006). EF5 binding and clinical outcome in human soft tissue sarcomas. International Journal of Radiation Oncology, Biology, Physics, 64, 922-927.
103. Evans, S. M., Judy, K. D., Dunphy, I., Jenkins, W. T., Hwang, W. T., Nelson, P. T., et al. (2004). Hypoxia is important in the biology and aggression of human glial brain tumors. Clinical Cancer Research, 10, 8177-8184.
104. Kaanders, J. H. A. M., Wijffels, K. I. E. M., Marres, H. A. M., Ljungkvist, A. S. E., Pop, L. A. M., van den Hoogen, F. J. A., et al. (2002). Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Research, 62, 7066-7074.
105. Leek, R. D., Landers, R. J., Harris, A. L., & Lewis, C. E. (1999). Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. British Journal of Cancer, 79, 991-995.
106. Murdoch, C., Giannoudis, A., & Lewis, C. E. (2004). Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood, 104, 2224-2234.
107. Leek, R. D., Lewis, C. E., Whitehouse, R., Greenall, M., Clarke, J., & Harris, A. L. (1996). Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Research, 56, 4625-4629.
108. Janssen, H. L., Hoebers, F. J., Sprong, D., Goethals, L., Williams, K. J., Stratford, I. J., et al. (2004). Differentiation-associated staining with anti-pimonidazole antibodies in head and neck tumors. Radiotherapy and Oncology, 70, 91-97.
109. Rajendran, J. G., Schwartz, D. L., O'Sullivan, J., Peterson, L. M., Ng, P., Scharnhorst, J., et al. (2006). Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clinical Cancer Research, 12, 5435-5441.
110. Rischin, D., Hicks, R. J., Fisher, R., Binns, D., Corry, J., Porceddu, S., et al. (2006). Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group Study 98.02. Journal of Clinical Oncology, 24, 2098-2104.
111. Lehtio, K., Eskola, O., Viljanen, T., Oikonen, V., Gronroos, T., Sillanmaki, L., et al. (2004). Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. International Journal of Radiation Oncology, Biology, Physics, 59, 971-982.
112. Ziemer, L. S., Evans, S. M., Kachur, A. V., Shuman, A. L., Cardi, C. A., Jenkins, W. T., et al. (2003). Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. European Journal of Nuclear Medicine and Molecular Imaging, 30, 259-266.
113. Fujibayashi, Y., Cutler, C. S., Anderson, C. J., McCarthy, D. W., Jones, L. A., Sharp, T., et al. (1999). Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: Ex vivo imaging of hypoxia in rats. Nuclear Medicine and Biology, 26, 117-121.
114. Yuan, H., Schroeder, T., Bowsher, J. E., Hedlund, L. W., Wong, T., & Dewhirst, M. W. (2006). Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). Journal of Nuclear Medicine, 47, 989-998.
115. Dehdashti, F., Grigsby, P. W., Mintun, M. A., Lewis, J. S., Siegel, B. A., & Welch, M. J. (2003). Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: Relationship to therapeutic response-A preliminary report. International Journal of Radiation Oncology, Biology, Physics, 55, 1233-1238.
116. Li, L., Yu, J., Xing, L., Ma, K., Zhu, H., Guo, H., et al. (2006). Serial hypoxia imaging with 99mTc-HL91 SPECT to predict radiotherapy response in nonsmall cell lung cancer. American Journal of Clinical Oncology, 29, 628-633.
117. Cooper, R. A., Carrington, B. M., Loncaster, J. A., Todd, S. M., Davidson, S. E., Logue, J. P., et al. (2000). Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiotherapy and Oncology, 57, 53-59.
118. Loncaster, J. A., Carrington, B. M., Sykes, J. R., Jones, A. P., Todd, S. M., Cooper, R., et al. (2002). Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. International Journal of Radiation Oncology, Biology, Physics, 54, 759-767.
119. Padhani, A. R., Krohn, K. A., Lewis, J. S., & Alber, M. (2007). Imaging oxygenation of human tumours. European Radiology, 17(4): 861-872.
120. Vaupel, P., Kallinowski, F., & Okunieff, P. (1989). Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Research, 49, 6449-6465.
121. Rodrigues, L. M., Howe, F. A., Griffiths, J. R., & Robinson, S. P. (2004). Tumor R2*is a prognostic indicator of acute radiotherapeutic response in rodent tumors. Journal of Magnetic Resonance Imaging, 19, 482-488.
122. Dunst, J., Stadler, P., Becker, A., Lautenschlager, C., Pelz, T., Hansgen, G., et al. (2003). Tumor volume and tumor hypoxia in head and neck cancers. The amount of the hypoxic volume is important. Strahlentherapie und Onkologie, 179, 521-526.
123. Brizel, D. M., Sibley, G. S., Prosnitz, L. R., Scher, R. L., & Dewhirst, M. W. (1997). Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. International Journal of Radiation Oncology, Biology, Physics, 38, 285-289.
124. Brizel, D. M., Dodge, R. K., Clough, R. W., & Dewhirst, M. W. (1999). Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiotherapy and Oncology, 53, 113-117.
125. Nordsmark, M., & Overgaard, J. (2000). A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiotherapy and Oncology, 57, 39-43.
126. Nordsmark, M., & Overgaard, J. (2004). Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer. Acta Oncológica, 43, 396-403.
127. 2 histography in patients with advanced head and neck cancer. Strahlentherapie und Onkologie, 177, 462-468.
128. 2 histography in patients with advanced head and neck cancer. Radiotherapy and Oncology, 57, 31-37.
129. Brizel, D. M. (1999). Human tumor oxygenation: The Duke University Medical Center experience. In P. Vaupel & D. K. Kelleher (Eds.), Tumor hypoxia (pp. 29-38). Stuttgart: Wissenschaftliche Verlagsgesellschaft.
130. Nordsmark, M., Alsner, J., Keller, J., Nielsen, O. S., Jensen, O. M., Horsman, M. R., et al. (2001). Hypoxia in human soft tissue sarcomas: Adverse impact on survival and no association with p53 mutations. British Journal of Cancer, 84, 1070-1075.
131. Bachtiary, B., Schindl, M., Potter, R., Dreier, B., Knocke, T. H., Hainfellner, J. A., et al. (2003). Overexpression of hypoxia-inducible factor 1α indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clinical Cancer Research, 9, 2234-2240.
132. Birner, P., Schindl, M., Obermair, A., Plank, C., Breitenecker, G., & Oberhuber, G. (2000). Overexpression of hypoxia-inducible factor 1α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Research, 60, 4693-4696.
133. Ishikawa, H., Sakurai, H., Hasegawa, M., Mitsuhashi, N., Takahashi, M., Masuda, N., et al. (2004). Expression of hypoxic-inducible factor 1α predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. International Journal of Radiation Oncology, Biology, Physics, 60, 513-521.
134. Dales, J. P., Garcia, S., Meunier-Carpentier, S., Andrac-Meyer, L., Haddad, O., Lavaut, M. N., et al. (2005). Overexpression of hypoxia-inducible factor HIF-1α predicts early relapse in breast cancer: Retrospective study in a series of 745 patients. International Journal of Cancer, 116, 734-739.
135. Schindl, M., Schoppmann, S. F., Samonigg, H., Hausmaninger, H., Kwasny, W., Gnant, M., et al. (2002). Overexpression of hypoxia-inducible factor 1α is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clinical Cancer Research, 8, 1831-1837.
136. Schoppmann, S. F., Fenzl, A., Schindl, M., Bachleitner-Hofmann, T., Nagy, K., Gnant, M., et al. (2006). Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer. Breast Cancer Research and Treatment, 99, 135-141.
137. Kyzas, P. A., Stefanou, D., Batistatou, A., & Agnantis, N. J. (2005). Hypoxia-induced tumor angiogenic pathway in head and neck cancer: An in vivo study. Cancer Letter, 225, 297-304.
138. Winter, S. C., Shah, K. A., Han, C., Campo, L., Turley, H., Leek, R., et al. (2006). The relation between hypoxia-inducible factor (HIF)-1α and HIF-2α expression with anemia and outcome in surgically treated head and neck cancer. Cancer, 107, 757-766.
139. De Schutter, H., Landuyt, W., Verbeken, E., Goethals, L., Hermans, R., & Nuyts, S. (2005). The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer, 5, 42.
140. Jonathan, R. A., Wijffels, K. I., Peeters, W., de Wilde, P. C., Marres, H. A., Merkx, M. A., et al. (2006). The prognostic value of endogenous
141. Oliver, R. J., Woodwards, R. T., Sloan, P., Thakker, N. S., Stratford, I. J., & Airley, R. E. (2004). Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC Translational Research Fund studies. European Journal of Cancer, 40, 503-507.
142. Hedley, D., Pintilie, M., Woo, J., Morrison, A., Birle, D., Fyles, A., et al. (2003). Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clinical Cancer Research, 9, 5666-5674.
143. Brennan, D. J., Jirstrom, K., Kronblad, A., Millikan, R. C., Landberg, G., Duffy, M. J., et al. (2006). CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clinical Cancer Research, 12, 6421-6431.
144. Hussain, S. A., Ganesan, R., Reynolds, G., Gross, L., Stevens, A., Pastorek, J., et al. (2007). Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. British Journal of Cancer, 96, 104-109.